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A little more than a year ago, we pub-
lished an editorial calling for papers de-
scribing research on human subjects
(1). Research on human subjects is be-
coming more feasible because of ad-
vances in methodology, and investiga-
tions on human subjects are needed to
advance the areas of human physiology
and disease covered by the Journal.
Patient-oriented research in particular
is often perceived as being applied
rather than basic research, but we rea-
soned that these demanding investiga-
tions can provide essential new biologi-
cal insights and have an important place
in our Journal, even though the depth
of mechanistic analysis is of necessity
more limited than in research on sim-
pler systems. To encourage submissions
of papers that involved human studies,
we made a commitment to judge them
on their capacity to advance the field
within the context of human research.
During the ensuing year, there
has  been a striking increase in the
number of submissions involving hu-
man subjects. In parallel, the number
of accepted papers that required hu-
man subjects increased more than
threefold in 2004 compared with 2003,
with 
 
 
 
10% of papers published in
2004 involving human subjects. We
also are pleased to have witnessed an
increased number of papers in which
human pathogens were studied but
without a need for human subjects. In
2004 the number of accepted papers
in this sphere was 
 
 
 
5%, a twofold in-
crease over 2003. These changes bring
some balance to experimental medicine
in the Journal, which clearly retains its
focus on “basic” research and disease
models in which deeper mechanistic
studies are possible. We hope that fu-
ture studies in these more tractable ex-
perimental systems will be inspired by
findings in patients.
 
Editorial challenges
 
The increase in human subject papers
has placed new demands on our peer
review process, especially as the in-
crease was superimposed on a high
submission rate in other areas. We are
still in the process of adjusting to these
new needs. Glenn Heller (Memorial
Sloan-Kettering Cancer Center, New
York, NY) and Madhu Mazumdar
(Weill Cornell Medical College, New
York, NY) have essential roles as Con-
sulting Biostatistics Editors. We also are
benefiting from the expert advice of a
number of referees who are familiar
with human research, several of whom
have joined our Advisory Editorial
Board. Most recently, we welcomed
David Hafler (Harvard Medical School,
Boston, MA), Kevin Tracey (North
Shore University Hospital, Manhasset,
NY), and Jean-Laurent Casanova (Necker
Medical School, Paris, France), who
bring broad expertise in autoimmunity,
inflammation, and infectious disease bi-
ology, respectively.
 
Evaluating human research
 
What are the Editors looking for when
they screen papers involving human
subjects? Three of the criteria are the
same as for all other papers: conceptual
novelty, state of the art approaches, and
the highest biological or therapeutic
importance. But there is one difference
with human papers relative to papers
with simpler experimental systems. Al-
though new mechanistic insight is essen-
tial, we do not necessarily expect the
depth of the mechanistic workup to be
comparable. Some of the human studies
we have published involve a detailed
analysis of a very small number of pa-
tients, whereas others involve a larger
number of subjects. Typically, the in-
vestigators were not able to pursue and
firmly establish mechanism in one paper
 
in a way that is expected of research
with mice. Nonetheless, the Editors
and most referees appreciate the con-
straints imposed by protocols that must
protect human subjects and, in each
case, the potential impact of the study
was judged to be high, in spite of these
limitations.
 
Experimental medicine in patients
 
The human subject papers that we have
published reflect a diversity of topics
and approaches. All are careful, system-
atic studies that provide new biological
insight, but very few have involved actual
experiments in patients using experi-
mental or approved interventions to
understand human physiology. This is
where our research enterprise needs to
grow and this will require much more
support than it is currently receiving.
As scientists, we are accustomed to dis-
secting and analyzing a system in a reduc-
tionist way, often in genetically altered
animals, to understand what is going on
and in many cases to inspire future
treatments. But in human subjects there
is often a need to take a more integra-
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tive and interventional approach and
try to direct physiology in order to un-
derstand disease processes and initiate
new therapies. In this issue, Pascual and
colleagues investigate the role of spe-
cific cytokines in the pathogenesis of a
form of childhood arthritis. They ob-
tained clues that interleukin-1 may be
involved, and show that blockade of
interleukin-1 results in marked amelio-
ration of this disease (2). Also in this issue,
Chang and colleagues, having found
earlier indications that NKT cells
might be providing protection against
cancer, assessed the capacity of mature
dendritic cells, charged with a synthetic
glycolipid, to expand NKT cells in pa-
tients with advanced cancer. They dis-
covered that the levels of NKT cells in
blood undergo prolonged expansion
and that this can be associated with in-
creased adaptive immunity to a third
party cytomegalovirus antigen (3). The
systematic study of a problem by inter-
vention in patients is a powerful form
of research, but it is currently a small
and relatively neglected part of our
profession. For research on patients to
grow we need to overcome many of
the obstacles and omissions that are
currently apparent in terms of training,
funding, and access to clinical-grade re-
agents (4).
A barrier to publishing in basic sci-
entific journals with broad readerships
is an additional obstacle to the develop-
ment of careers in patient-based research.
Surely the increase in submitted and
accepted papers that we have seen reflects
that investigators who study human sub-
jects want to see their work published
in these journals. The problem has
been that most basic science journals
simply are not prepared to get excited
about the best findings that can be
made in human subjects. We are ex-
cited by the new insights into human
disease and physiology that we have
published over the past 18 months.
Nevertheless, the 
 
JEM
 
 and other journals
may not get to publish more experi-
mental medicine in patients unless the
research community more broadly over-
comes the difficulties encountered by
investigators who study human subjects.
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